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Abstract
Objective: Annexin A1 (ANXA1) is suggested to have anti-inflammatory function. How-
ever, the precise function of ANXA1 has remained unclear. In this study, we therefore 
examined the potency of ANXA1 in regulating reactive oxygen species (ROS) production 
and suppressing pro-inflammatory responses in PC12 cells induced by 1-methyl-4-phe-
nylpyridinium (MPP+).   
Materials and Methods: In this experimental study, cDNA of ANXA1 was cloned and 
inserted to the PGL268 pEpi-FGM18F vector to produce a recombinant PGL/ANXA1 vec-
tor for transfection into the PC12 cells.  ANXA1 transfected cells were then treated with 
MPP+. Apoptosis and the content of pro-inflammatory factors including ROS, Interlukin-6 
(IL-6), inducible nitric oxide synthase (iNOS) and nuclear factor-kappa B (NF-κB) were 
assessed by flow-cytometry, real-time quantitative polymerase chain reaction (RT-qPCR) 
and western blot in ANXA1-transfected cells and the data were compared with those ob-
tained from mock and control cells.           
Results: Data revealed that overexpression of ANXA1 is associated with decreased lev-
els of ROS and expression level of IL-6 and iNOS transcripts, and NF-κB protein in MPP+ 
treated PC12 cells.                   
Conclusion: ANXA1 may be considered as an agent for prevention of neurodegenerative 
or inflammatory conditions.      
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Introduction
Parkinson’s disease (PD) is characterized by 
death of dopaminergic neurons in Substantia Nigra 
pars compacta (SNpc), a region of the midbrain, 
generation of lewy bodies and neuroinflammation 
(1-3). Although the exact origin of neuronal degen-
eration in PD has not been well understood, several 
hypotheses have been postulated for the etiology of 
PD onset including age, genetic factors, oxidative 
stress, mitochondrial dysfunction and environmen-
tal toxins (4-6). Neuropathological manifestations 
of PD are associated with neurological impairment 
that results from pro-inflammatory factors. These 
factors are the major determinants of PD patho-
genesis which are induced by infectious or toxic 
agents (7). Neuroinflammation is associated with 
presence of activated microglia, reactive astro-
cytes and adaptive immune cells in parenchyma of 
 CELL JOURNAL(Yakhteh), Vol 18, No 2, Jul-Sep (Summer) 2016 198
central nervous system (CNS). Pro-inflammatory 
cytokines, and reactive oxygen and nitrogen spe-
cies (ROS/RNS) are secreted by these cells which 
lead to the progress of PD (8). Oxidative stress and 
cell apoptosis play main roles in pathogenesis of 
PD (9). Among pro-inflammatory mediators, inter-
lukin-1 beta (IL-1β), IL-6, tumor necrosis factor-
alpha (TNF-α), cyclooxygenase 2 (COX-2) and 
inducible nitric oxide synthase (iNOS) have im-
portant roles in generating inflammation (10-13). 
The key mediator of inflammatory responses is 
NF-κB, which acts as a nuclear transcription fac-
tor. Normaly, inactivated nuclear factor-kappa B 
(NF-κB),     is bound to inhibitor of kappa B (IκB) 
in the cytosol. Under inflammatory conditions, 
phosphorylated IκB is dissociated from NF-κB. 
Free activated NF-κB translocates to the nucleus 
which induces the expression of inflammatory 
genes including IL-1β, IL-6, TNF-α and COX-2. 
Subsequently, the inflammatory condition is ac-
companied by the activation of mitogen-activated 
protein kinases (MAPKs) including extracellular 
signal-regulated kinase (ERK), c-Jun N-terminal 
kinase (JNK) and p38 (14-16).
Annexin A1 (ANXA1) or lipocortin is a member 
of the annexin protein superfamily and is defined as a 
calcium-dependent phospholipid binding protein that 
plays different roles in various biological systems. Re-
cently, it has been shown to act as a regulator not only 
for cellular functions such as anti-inflammatory ef-
fects, cell proliferation and apoptosis, but also for cell 
differentiation (17, 18). Previous studies have dem-
onstrated that ANXA1 acts as a regulator of inflam-
mation by inhibiting inflammatory factors such as 
phospholipase A2 (19) and NF-κB (20). Several stud-
ies have also reported a preventive role of ANXA1 
against cell death in vitro and in vivo (21, 22).
Disruption of mitochondrial complex I activ-
ity in the electron transport chain occurs in SNpc, 
skeletal muscle, and platelets of PD patients 
(23-25).1-methyl-4-phenylpyridinium (MPP+), 
a toxic metabolite of 1-methyl-4-phenyl-1, 2, 3, 
6-tetrahydropyridine (MPTP), is a mitochondrial 
complex I inhibitor (26, 27), which is used for in-
duction of oxidative stress, apoptosis and inflam-
mation, especially in dopaminergic neurons. PC12 
cells have served as a convenient model cell for 
studying neuronal development and function.
 One of the main interests in the medical field is 
finding new factors for inflammation relief, espe-
cially in neurodegenerative diseases. As the poten-
tial role of ANXA1 has so far not been studied, the 
aim of the present study is to assess the possible 
inhibitory role of ANXA1 against MPP+ induced 
inflammation and apoptosis in PC12 cells.
Materials and Methods
The most reagents in this experimental study 
were supplied by Sigma (CA, USA) unless indi-
cated otherwise.
Ethical issue 
This study was approved by the Ethical Commit-
tee of Royan Institute (Project ID. 920010).
Cell culture and transfection of AgeI-ANXA1- 
FLAG in PC12 cells 
PC12 cells (obtained from Royan Institute for 
Stem Cell Biology and Technology, Iran) were 
placed on 0.01% poly-L-lysine-coated 6-well dish 
in presence of Dulbecco’s modified Eagle’s me-
dium (DMEM, Life Technologies, CA, USA) sup-
plemented with 10% fetal calf serum (FCS, Life 
Technologies), and 5% horse serum  (Life Tech-
nologies) at 37˚C. PC12 cells were transfected 
with either pEPi FGM18F PGL-268 or pEPi FG-
M18F PGL-268/AgeI-ANXA1-FLAG (described 
in Supplementary Material Information and be-
low) by Lipofectamine LTX reagent based on the 
manufacturer’s instructions (Invitrogen, USA).
Cell staining 
Cells were cultured on glass coverslips and washed 
the day after with phosphate buffer saline (PBS-, Life 
Technologies) and fixed with 4% paraformaldehyde 
(Sigma) in PBS- for 20 minutes at room temperature. 
Cells were then permeabilized with 0.2% triton X-100 
(Sigma) at 37˚C for 30 minutes. Cells were washed 
again and incubated for 1 hour with mouse anti-tyros-
ine hydroxylase (TH, 1:200, Sigma). Next, cells were 
incubated for 1 hour with labeled rabbit anti-mouse 
secondary antibody (Milipore, USA). For nuclei 
staining, cells were incubated for 3 minutes with 10 
µg/mL 4´, 6-diamidino-2-phenylindole, dihydrochlo-
ride (DAPI, Sigma) in bovine serum albumin (BSA, 
Sigma). After washing, coverslips were mounted on 
glass slides and analyzed under a fluorescent micro-
scope (Olympus, Japan) with images acquired with an 
Olympus DP70 camera (Olympus, Japan).
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Viability assay 
The(3-(4 ,5-dimethyl thiazol-2-yl) -5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) (MTS) assay was performed to evaluate 
the number of viable cells based on mitochondrial 
dehydrogenase activity. Upon tetrazolium absorption 
into living cells, it is converted to formazan by mi-
tochondrial dehydrogenase enzyme activity. There-
fore, accumulation of formazan reflects the activity 
of mitochondria and is associated with cell viability. 
Briefly, PC12 cells (104 cells/well) were plated in 96-
well plates (Techno Plastic Products, Switzerland) 
and treated with different concentrations of MPP+ 
for 24 hours at 37˚C. Cells were washed gently with 
PBS.  Twenty μL of MTS (0.5 mg/mL) and 200 μL of 
medium were added to each well for 4 hours at 37˚C. 
The supernatant was removed and 150 μL of dimethyl 
sulfoxide (DMSO, Sigma) was added to each well. 
Optical density (OD) was assessed at 570 nm in an 
ELISA microplate reader (Awareness, USA).
Quantification of apoptosis   
Apoptosis was assessed through annexin V stain-
ing by flow-cytometry in untransfected, mock and 
ANXA1-transfected PC12 cells treated with MPP+. 
To do this, approximately 6×105 cells were plated 
in 6-well dishes and treated with MPP+ at 37˚C for 
24 hours. Cells were washed with PBS and stained 
with fluorescein isothiocyanate (FITC)-coupled anti-
annexin V antibody (Abcam, UK) on ice at 4˚C for 
20 minutes. Flow cytometry was carried out with a 
FACSCalibur flow cytometer (Becton Dickinson, 
USA). Stained cells were considered apoptotic and 
104 events were recorded for each analysis.
Assessment of oxidative stress    
ROS production was measured with 2´,7´-dichloro-
dihydrofluorescein diacetate (DCFH-DA) staining for 
all groups of MPP+ treated PC12 cells with a FAC-
SCalibur flow cytometer (Becton Dickinson, USA). 
DCFH-DA is a non-fluorescent dye that freely pen-
etrates into the cell and is enzymatically hydrolyzed 
by intracellular esterases to DCFH. This is then oxi-
dized to the fluorescent DCF by ROS. Briefly, cells 
were seeded in 6-well plates (6×105 cells per well) 
and were pretreated with 800 μM MPP+ for 24 hours 
and stained with DCFH-DA (10 μM) for 20 mins in 
room temperature. For each sample, 104 events were 
recorded using flow-cytometry.
Real-time quantitative polymerase chain reaction 
analysis 
Total RNA was extracted from cells using the Trizol 
reagent. RNA purity was tested by NanoDrop Spec-
trophotometer (Biochrom WPA, UK). One µg of to-
tal RNA was used in a reverse-transcription reaction 
utilizing random hexamer primers according to the 
manufacturer’s protocol (TaKaRa, Japan). Next, 1 μL 
of the resulting cDNA was amplified in the Step One 
plus Real-Time PCR thermal cycler (Applied Biosys-
tems, USA) in a total volume of 10 μL containing 5 μL 
of SYBR Green Master Mix (ROX) (TaKaRa, Japan) 
along with gene-specific primers. Transcript levels of 
target genes were normalized to the expression level 
of GAPDH. Differential expression was analyzed ac-
cording to the 2-ΔΔCt method. Primer pairs (Table 1) 
were designed by the Beacon designer (Version 7.2, 
premierbiosoft company, CA, USA) and Perl-primer 
softwares and synthesized by Metabion (Germany).
Table 1: List of primers
Gene Primer sequence (5´-3´) Product length (bp)
ANXA1 (Human) F: GAGGACTTTGGTGTGAATG
R: GGTGGTAAGGATGGTATTG
114
IL-6 (Rat) F: TCCAGCCAGTTGCCTTCTTG
R: GGTCTGTTGTGGGTGGTATCC
106
iNOS (Rat) F: AAGAGACGCACAGGCAGAG
R: CAGGCACACGCAATGATGG
125
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Western blot analysis   
Protein isolation was performed simulta-
neously with RNA extraction from the cells. 
Briefly, 30 µg of extracted protein was loaded 
on sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins were 
then transferred onto a polyvinylidene fluoride 
(PVDF) membrane (Biorad, Germany), and 
blocked with 5% (w/v) non-fat dried milk (Mer-
ck, Germany) in PBS. The membrane was la-
beled with the rabbit anti-NF-κB p65 antibody 
(1:500, Abcam) or anti-GAPDH (Dako Cyto-
mation, Denmark). The secondary anti body 
was goat anti-rabbit IgG-HRP (1:16000, Santa 
Cruz, USA). In case of the Flag antibody, HRP-
conjugated mouse anti-Flag antibody was used. 
Immunoreactive bands were visualized using 
an Amersham enhanced chemiluminescence 
(ECL) Advance Western Blotting Detection Kit 
(GE Healthcare, Germany). Western blots were 
carried out in triplicate from three separate cul-
tures. The band intensity of NF-κB and p65 was 
compared that of GAPDH.
Statistical analysis   
All experiments were performed at least under 
three independent treatments of replicated ob-
servations. Under each treatment, samples were 
tested in triplicate. SPSS 18.0 (IBM, IL, USA) 
was used for statistical analysis and data were ex-
pressed as mean ± SEM. Data were analyzed by 
the independent t test and one-way ANOVA. Fur-
thermore, for all analysis, P<0.05 was considered 
statistically significant.
Results
PC12 cells overexpressing ANXA1 have normal 
morphology 
Overexpression of ANXA1-FLAG CDS was 
confirmed by RT-qPCR showing significant 
expression in transfected cells (Fig.1A). Fur-
thermore, western blot analysis confirmed the 
results obtained by RT-qPCR (Fig.1B). When 
stained with anti-TH antibody, transformed 
cells were morphologically similar to normal 
un-transfected PC12 cells. By having similar 
expression of TH (Fig.1C). 
Fig.1: Characterization of ANXA1-FLAG transfected PC12 cells. 
A. Ectopic expression of ANXA1-FLAG. Relative expression of 
ANXA1-FLAG was quantified and normalized to the amount of 
GAPDH transcript, B. Western blot analysis to quantify the pro-
tein content of ANXA1-FLAG. GAPDH was used as a loading con-
trol, and C. PC12 cells were stained with an antibody against TH. 
Nuclei were counterstained with 4′, 6-diamidino-2-phenylindole 
(DAPI). Bar is 200 µm. It should be noted that the staining pat-
tern in ANXA1 transfected cells was similar to untransfected 
cells (Unt). ANXA1 and Mock represent stably transfected cells 
with pEPi FGM18F PGL-268/ANXA1-FLAG and pEPi FGM18F PGL-
268 plasmids respectively. ANXA1; Annexin A1.
Viability of PC12 cells induced by MPP+   
Results of MTS assay revealed that 800 µM of 
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cells (by 50%) (Fig.2A). Also, flow-cytometry in-
dicated an enhanced rate of apoptosis when 800 
µM of MPP+ was applied (Fig.2B). Therefore, 
further experiments were carried out at this con-
centration to determine whether ANXA1 could 
counter the inflammation.
Fig.2: PC12 cell proliferation and apoptosis modulation under 
MPP+ treatment. A. Viable cell estimation by MTS assay under 
treatment with different concentrations of MPP+ and B. Flow-
cytometry analysis of apoptotic cells under treatment with dif-
ferent concentrations of MPP+. Results were expressed as the 
percentage of cell number after treating with various concentra-
tions of MPP+ relative to the cell number of the control sample. 
Values represent mean of triplicate independent experiments 
± SEM. *; Indicates significant difference between treated and 
the control sample (0 µM of MPP+) at P<0.05, MPP+; 1-methyl-
4-phenylpyridinium and MTS; (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium).
PC12 cells overexpressing ANXA1 have a similar 
apoptosis rate    
Measurement of apoptosis induced by MPP+ in 
PC12 cells indicated no significant difference in the 
number of Annexin V positive cells among groups 
(Fig.3).  This observation indicated that despite the 
induction of apoptosis by MPP+, ANXA1-FLAG 
was not able to reverse this condition. 
Fig.3: Apoptosis rate constancy in ANXA1 transfected cells. The 
number of annexin V positive cells was not significantly different 
between the groups. Results were expressed as the percentage 
of cell number after treating with various concentrations of MPP+ 
relative to the cell number of the untreated sample. Values repre-
sent mean of triplicate independent experiments ± SEM. ANXA I 
and Mock represent stably transfected cells with pEPi FGM18F 
PGL-268/ANXA1-FLAG and pEPi FGM18F PGL-268 plasmids re-
spectively. Unt; Untransformed cells, ANXA1; Annexin A1 and 
MPP+; 1-methyl-4-phenylpyridinium.
Overexpression of ANXA1 negatively regulates 
the reactive oxygen species production and 
pro-inflammatory factors induced by MPP+   
To evaluate the effect of ANXA1 against intra-
cellular amounts of ROS production, DCFHDA 
staining was performed. Results showed that 
positive stained cells (green fluorescence) were 
significantly more in untransfected and mock 
groups than the transfected group (P<0.05) 
(Fig.4A).
Furthermore, the anti-inflammatory effect 
of ANXA1 was estimated by two different 
methods.  RT-qPCR results showed transcrip-
tion levels of IL-6 and iNOS reduced signifi-
cantly in ANXA1-FLAG transfected cells com-
pared with other groups under MPP+ treatment 
(Fig.4B, C). Western blot results were consist-
ent with those of RT-qPCR. As shown in Figure 
5, ANXA1 overexpression was associated with 
significant reduction of NFκB protein level in 
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under MPP+ treatment. These data suggest that 
ANXA1-FLAG expression is capable to decrease 
transcription levels of IL-6 and iNOS and intra-
cellular amounts of ROS as well as significantly 
reduce NFκB protein level in PC12 cells.
Fig.4: MPP+ induced inflammation was significantly decreased in 
ANXA1 transformed cells. A. The content of ROS was decreased 
in ANXA1 transfected cells, B. and C. Relative transcript levels 
of inflammatory markers, iNOS and IL6, were reduced in ANXA1 
transfected cells under MPP+ induced inflammatory conditions. 
*; Indicates significant difference between treated and control 
samples, Unt; Untransformed cells, ANXA1; Annexin A1, MPP+; 
1-methyl-4-phenylpyridinium, IL-6; Interlukin-6 and iNOS; Induc-
ible nitric oxide synthase.
Fig.5: Significant reduction of NF-κB content in ANXA1 trans-
formed cells. *; Indicates significant difference between treated 
and control samples, ANXA1; Annexin A1 and NF-κB; Nuclear 
factor-kappa B.
Discussion
In this study, the anti-inflammatory role of 
ANXA1 was shown. A variety of functions have 
been attributed to ANXA1 including regulation of 
cell proliferation, apoptosis, and cell growth (17, 
18). Although there is no evidence for ANXA1 as 
a disease-causing gene, it is clear that its expres-
sion change can contribute to the pathogenesis of 
inflammatory diseases and even cancer (28, 29). 
Our analyses revealed that NF-κB level reduced 
in ANXA1 transfected cells under inflammation. 
NF-κB, as a master transcription factor, is acti-
vated by various stimuli associated with inflam-
mation. NF-κB activity results in the expression 
of pro-inflammatory mediators including IL-1β, 
IL-6, TNF-α and COX-2 (14-16). Our results 
showed that ANXA1 overexpression also reduced 
IL-6 and iNOS transcript levels in MPP+ treating 
transformed PC12 cells. A previous study revealed 
that ANXA1 expression inhibited transcriptional 
activity of NF-κB by preventing NF-κB binding 
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asone, trigger the anti-inflammatory properties 
through induction of endogenous ANXA1 expres-
sion, which is correlated with the inhibition of 
NF-κB activity (19, 30). Our findings revealed that 
ANXA1 overexpression significantly reduced NF-
κB content in PC12 cells, suggesting that ANXA1 
may play an anti-inflammatory role.
Pro-inflammatory cytokines such as IL-6 are 
increased in SNpc, striatum, cerebral spinal flu-
id (CSF) and microglia in PD patients (31-34). 
These components are the pro-inflammatory 
mediators released during microglial activation. 
Although they may initially operate as neuro-
protective agents, they act synergistically to 
produce inflammation-related neuronal damage 
in later stages (32). Hence, reduced amounts of 
IL-6 and other inflammatory parameters under 
MPP+ treatment in ANXA1 transfected PC12 
cells group suggests that ANXA1 plays a promi-
nent role in inflammation recovery and may be 
applied as a neuroprotective agent when inflam-
mation occurs.
Oxidative stress is a mediator for nerve cell death 
in inflammation. Previous studies have reported 
that apoptotic death of dopaminergic neurons may 
be initiated by oxidative stress. MPP+ as an ac-
tive toxin produces oxidative stress in PC12 cells. 
MPP+ is actively transported to the mitochondria 
and prevents the function of complex I of the elec-
tron transport chain, thus resulting in production 
of ROS (35). We found that ROS generation and 
iNOS expression were down-regulated in ANXA1 
transfected PC12 cells under MPP+ treatment 
while apoptosis remained unchanged. This sug-
gests that ANXA1 may protect PC12 cells against 
ROS-induced injuries. A possible explanation for 
this dichotomy is that apoptosis induction with 
MPP+ treatment in PC12 cell may have occurred 
via different pathways in which ANXA1 was not 
involved. Presumably, MPP+ could stimulate cell 
death through different mechanisms beside ROS 
production. Examples of such mechanisms are 
ER stress, p53 activation, release of cytochrome 
c from mitochondria, mitochondrial swelling, 
Ca2+ release, p38 activation and other MAP kinase 
pathways. It remains unknown, however, which 
of these mechanisms is involved in cell death in 
MPP+-treated PC12 cells. Further to our findings, 
Solito et al. (36) reported that exogenous ANXA1 
stimulated apoptosis in human neutrophils and 
endogenous ANXA1 was released from apoptot-
ic neutrophils which stimulated macrophages to 
phagocyte these apoptotic cells (37). LPS-induced 
endotoxic shock in ANXA1–/– mice was also cor-
related with increase in TNFα, IL-1 and IL-6 levels 
in the blood when compared with wild-type mice 
(19). Taken together, ANXA1 is unlikely to be in-
volved in inhibition of apoptosis in PC12 cells as 
a dopaminergic cells. ANXA1 may act as a down-
regulator for the innate immune cells, in particular 
in generation of pro-inflammatory mediators. In-
terestingly, exogenous ANXA1 or an N-terminal 
portion of ANXA1 peptide, was able to ameliorate 
inhibitory effects of glucocorticoids, including in-
hibition of leukocyte recruitment at inflammatory 
sites (38).
Conclusion
ANXA1, as a potent neuroprotective agent, may 
prevent mitochondrial functions from damage and 
interfere with the generation of ROS, iNOS and 
pro-inflammatory mediators. One of the future 
directions of this study is to extend these experi-
ments to differentiated PC12 cells or primary cul-
tured dopaminergic cells.  
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